Determination of metabolites of prostanozol in human urine by LC/ESI/MS and GC/TOF-MS

This research examined prostanozol and its metabolites in urine of women who took the medicine (prostanozol). Prostanozol and its metabolites were successfully separated and detected by using LC/ESI/MS and GC/TOF-MS. Mass spectrum of LC/ESI/MS estimated molecular weight of Prostanozol and its metabolites and that of GC/TOF-MS verified them. For M1, carbon number 17 of Prostanozol substituted to a keto group and it is called 17-keto-Prostanozol. M2 turned out to be hydroxy-17-keto-Prostanozol. It came from substitution of one hydroxyl group of pyrazole nucleus and A-ring of M1. Substitution of one hydroxyl group of B-ring or C-ring became M3, hydroxy-17-keto-Prostanozol. M4 was found to be a hydroxy-17-keto-Prostsnozol transposed from one hydroxyl group to a D-ring. M5 has a hydroxyl group of carbon number 17. One hydroxyl group is substituted from B-ring or C-ring and it is assumed to be hydroxy-17-hydroxy-Prostanozol. M6 was turned out to be dihydroxy-17-keto-Prostanozol transposed from one hydroxyl group to pyrazole nucleus or A-ring and to B-ring or C-ring. Like M6, M7 has a keto group at carbon number 17 and was identified as dihydroxy-17-keto-Prostanozol. M7 has one hydroxyl group at pyrazole nucleus or A-ring and also at D-ring. At last M8 was found to be dihydroxy-17-hydroxy-Prostanozol. Pyrazole nucleus or A-ring has got one hydroxyl group and other rings were substituted to another hydroxyl group. From above, M5, M7 and M8 were verified as new metabolites that were not discovered yet. Prostanozol and all of the 8 metabolites formed glucuronic conjugates as a result of conjugation reaction test in human body. Some of 8 metabolites were excreted without forming conjugates. Particularly M6 and M7 were excreted as sulfate conjugates.

LC/ESI/MS와 GC/TOF-MS를 이용한 인체뇨시료에서의 Prostanozol 대사체 검출

약물(Prostanozol)을 복용한 여성을 대상으로 한 뇨시료 중에 함유된 Prostanozol 및 그 대사체들을 검출하기 위해 LC/ESI/MS와 GC/TOF-MS를 이용하여 효과적으로 분리 및 검출하였고, LC/ESI/MS의 질량스펙트럼으로부터는 각각의 분자량을 추정하였으며 GC/TOF-MS로는 이들을 확인하였다. M1은 Prostanozol의 17번 탄소가 케톤기로 치환된 17-keto-Prostanozol, M2는 M1에서 pyrazole nucleus 와 Aring에 한 개의 히드록시기가 치환된 hydroxy-17-keto-Prostanozol, M3는 B-ring 또는 C-ring에 한 개의 히드록시기가 치환된 hydroxy-17-keto-Prostanozol, M4는 한 개의 히드록시기가 D-ring에 치환된 hydroxy-17-keto-Prostsnozol로 확인되었으며 M5는 17번 탄소 위치에 히드록시기를 갖고 B-ring 또는 C-ring에서 하나의 히드록시기가 치환된 hydroxy-17-hydroxy-Prostanozol로 추정되며 M6은 17번 탄소 위치에 케톤기를 갖고 pyrazole nucleus 혹은 A-ring에 하나의 히드록시기를 또한 B-ring 또는 C-ring에 또 하나의 히드록시기가 치환된 dihydroxy-17-keto-Prostanozol, M7은 M6와 같이 17번 탄소에 케톤기를 갖으며 pyrazole nucleus 혹은 A-ring에 하나의 히드록시기를, 또한 D-ring에 또 하나의 히드록시기를 가진 dihydroxy-17-keto-Prostanozol로 확인되었다. 마지막으로 M8은 pyrazole nucleus 혹은 A-ring에 하나의 히드록시기를 갖고 그 외의 ring에 또 다른 히드록시기가 치환된 dihydroxy-17-hydroxy-Prostanozol임을 확인할 수 있었다. 이중 M5, M7, 그리고 M8은 지금까지 밝혀지지 않았던 새로운 대사체였다. 체내에서의 포합반응 여부를 확인한 결과 Prostanozol과 8종의 모든 대사체가 글루쿠론산 포합체를 형성하였고, 8종의 대사체 중 일부는 포합체를 형성하지 않고도 배출되며 특히 M6과 M7은 황산 포합체로도 배설되는 것을 확인할 수 있었다.